This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016;57(3):505-6.

doi: 10.3109/10428194.2015.1102247. Epub 2015 Dec 23.

Combination therapies for MDS and AML: Does one plus one equal one?

Swapna Thota¹, Mikkael A Sekeres¹

Affiliations

PMID: 26428702
DOI: 10.3109/10428194.2015.1102247

Comment

Combination therapies for MDS and AML: Does one plus one equal one?

Swapna Thota et al. Leuk Lymphoma. 2016.

. 2016;57(3):505-6.

doi: 10.3109/10428194.2015.1102247. Epub 2015 Dec 23.

Authors

Swapna Thota¹, Mikkael A Sekeres¹

Affiliation

¹ a Leukemia Program, Cleveland Clinic Taussig Cancer Institute , Cleveland , OH , USA.

PMID: 26428702
DOI: 10.3109/10428194.2015.1102247

No abstract available

PubMed Disclaimer

Comment on

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R, Garcia JS, Percival ME, Berube C, Coutre S, Gotlib J, Greenberg P, Liedtke M, Hewitt R, Regan K, Williamson C, Doykan C, Cardone MH, McMillan A, Medeiros BC. Narayan R, et al. Leuk Lymphoma. 2016;57(3):609-15. doi: 10.3109/10428194.2015.1091930. Epub 2015 Oct 13. Leuk Lymphoma. 2016. PMID: 26374199 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal